PP
PBYI icon

PDT Partners’s Puma Biotechnology PBYI Stock Holding History

PDT Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,131
Closed -$34K – 829
2024
Q4 		$34K Hold
11,131
– – ﹤0.01% 700
2024
Q3 		$28.4K Hold
11,131
– – ﹤0.01% 710
2024
Q2 		$36.3K Buy
+11,131
New +$48.9K ﹤0.01% 654
2023
Q3 		– Sell
-21,946
Closed -$77.5K – 655
2023
Q2 		$77.5K Hold
21,946
– – 0.01% 539
2023
Q1 		$67.8K Buy
21,946
+2,800
+15% +$10.6K 0.01% 546
2022
Q4 		$81K Buy
+19,146
New +$66.1K 0.01% 587
2022
Q2 		– Sell
-46,494
Closed -$134K – 1106
2022
Q1 		$134K Sell
46,494
-21,597
-32% -$55.9K 0.01% 848
2021
Q4 		$207K Buy
68,091
+1,363
+2% +$5.92K 0.02% 760
2021
Q3 		$468K Buy
66,728
+606
+0.9% +$4.54K 0.03% 494
2021
Q2 		$607K Sell
66,122
-5,733
-8% -$58.1K 0.04% 474
2021
Q1 		$698K Sell
71,855
-10,105
-12% -$113K 0.05% 442
2020
Q4 		$841K Sell
81,960
-46,358
-36% -$469K 0.06% 357
2020
Q3 		$1.29M Sell
128,318
-60,220
-32% -$613K 0.09% 267
2020
Q2 		$1.97M Sell
188,538
-15,700
-8% -$162K 0.13% 212
2020
Q1 		$1.72M Buy
204,238
+36,638
+22% +$356K 0.14% 169
2019
Q4 		$1.47M Sell
167,600
-82,809
-33% -$686K 0.09% 226
2019
Q3 		$2.7M Buy
250,409
+62,709
+33% +$677K 0.16% 167
2019
Q2 		$2.39M Buy
187,700
+65,600
+54% +$1.51M 0.14% 168
2019
Q1 		$4.74M Sell
122,100
-50
-0% -$1.53K 0.27% 121
2018
Q4 		$2.49M Buy
+122,150
New +$3.67M 0.14% 169
2015
Q3 		– Sell
-3,692
Closed -$431K – 1487
2015
Q2 		$431K Buy
+3,692
New +$669K 0.01% 1021
2013
Q4 		– Sell
-9,924
Closed -$533K – 1030
2013
Q3 		$533K Buy
9,924
+2,379
+32% +$128K 0.01% 1017
2013
Q2 		$335K Buy
+7,545
New +$266K 0.01% 1223

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PDT Partners's PBYI Position: Q1 2025 in Review

PDT Partners sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 11,131 shares — an estimated $34K sold.

PDT Partners first reported a position in PBYI in Q2 2013 and held it in 23 quarters. The position peaked at $4.74M in Q1 2019. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

  • PDT Partners reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 11,131 Puma Biotechnology shares in Q1 2025, an estimated $34K.
  • PDT Partners first reported a position in Puma Biotechnology in Q2 2013 and held it in 23 quarters.
  • PDT Partners's Puma Biotechnology position peaked at $4.74M in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.